Toll or toll-free adjuvant path toward the optimal vaccine development. | J Clin Immunol;27(4): 363-71, 2007 Jul. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL TCIM Americas

Traditional, Complementary and Integrative Medicine in the Americas VHL

Subject descriptor lookup Advanced Search

Toll or toll-free adjuvant path toward the optimal vaccine development.

Ishii, Ken J; Akira, Shizuo.

Affiliation

Ishii KJ; Exploratory Research for Advanced Technology (ERATO), Japan Science and Technology Agency (JST), Osaka University, Suita, Osaka 565-0871, Japan. kenishii@biken.osaka-u.ac.jp

J Clin Immunol ; 27(4): 363-71, 2007 Jul.

Article in En | MEDLINE | ID: mdl-17370119

Subject(s)

Adjuvants, Immunologic; Toll-Like Receptors/physiology; Vaccines; Humans; Immunity, Innate/drug effects; Immunization; Signal Transduction/immunology; Toll-Like Receptors/immunology; Vaccines/pharmacology

Search on Google

Database: MEDLINE Main subject: Vaccines / Adjuvants, Immunologic / Toll-Like Receptors Language: En Journal: J Clin Immunol Year: 2007 Type: Article Affiliation country: Japan

Search on Google

Database: MEDLINE Main subject: Vaccines / Adjuvants, Immunologic / Toll-Like Receptors Language: En Journal: J Clin Immunol Year: 2007 Type: Article Affiliation country: Japan